A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1503 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Stefan Grudén und 6 weiteren Autor:innen. Beteiligte Einrichtung: Empros Pharma AB, Solna, Sweden. Hauptthemen laut MEDLINE: Orlistat, Anti-Obesity Agents, Acarbose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Empros Pharma AB.
Abstract (Originalsprache)
A new modified‐release oral formulation combines acarbose and orlistat (MR‐OA) to enhance efficacy and reduce adverse effects through controlled drug release. This study aims to compare the pharmacodynamic properties of the orlistat component of MR‐OA (MR‐O) with a conventional orlistat product, Xenical (Conv‐O), analyzing the percentage of fecal fat excretion. In addition, the pharmacokinetic properties of the complete formulation, MR‐OA, were compared with Conv‐O. In Part I of the study, 20 healthy volunteers were randomized in a single‐blind, crossover trial to take MR‐O or Conv‐O (120‐mg orlistat) 3 times daily for 9 days. Fecal fat was measured at baseline and after each treatment. MR‐O and Conv‐O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence. Adverse events were few and generally rated as mild. In Part II, participants received MR‐OA and then Conv‐O, with blood samples collected for 12 hours to measure orlistat and acarbose levels. Orlistat's peak concentration stayed below 5 ng/mL, and acarbose plasma levels were mostly undetectable, indicating minimal systemic absorption. This shows that the new weight loss product MR‐OA retains the dietary energy loss pathway used in Conv‐O. Consistent with previous studies, minimal systemic absorption of orlistat and acarbose was observed for MR‐OA, confirming that no significant alteration of the original substances occurs when modifying their release.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Empros Pharma AB, Solna, Sweden.
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
- Clinical Trial Consultants AB, Uppsala, Sweden.
- Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
- Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Förderung
- Empros Pharma AB
Zitieren
APA
Grudén, S., Forslund, A., Litorp, H., Kuusk, S., Alderborn, G., Söderhäll, A., & Holmbäck, U. (2025). A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1503
Vancouver
Grudén S, Forslund A, Litorp H, Kuusk S, Alderborn G, Söderhäll A, et al. A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1503
BibTeX
@article{Grudn2025,
author = {Grudén, Stefan and Forslund, Anders and Litorp, Helena and Kuusk, Sandra and Alderborn, Göran and Söderhäll, Arvid and Holmbäck, Ulf},
title = {A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1503}
}
EUVIMED